| Ligand | Protein Symbol | Approved Name | Docking Scores |
Similarity Score |
Best Match | ||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |||||
| Amantadine | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -6.04 | -6.27 | -6.51 | 22.22% | CHEMBL146942 |
| Alfentanil | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -7.92 | -8.19 | -8.21 | 38.51% | CHEMBL148110 |
| Pimecrolimus | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -9.61 | -7.18 | 10.39 | 31.96% | CHEMBL442 |
| Levacetylmethadol | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -7.46 | -7.24 | -8.02 | 42.37% | CHEMBL79693 |
| Rofecoxib | 5HT1B_HUMAN | 5-hydroxytryptamine receptor 1B | -10.04 | -9.37 | -9.26 | 31.16% | CHEMBL188486 |
| Amantadine | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -5.91 | -6.29 | N/A | 40.00% | CHEMBL334255 |
| Alfentanil | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -8.30 | -7.10 | N/A | 43.15% | CHEMBL4066435 |
| Pimecrolimus | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | 0.63 | 20.42 | N/A | 45.83% | CHEMBL473781 |
| Levacetylmethadol | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -8.16 | -7.04 | N/A | 56.41% | CHEMBL936 |
| Rofecoxib | 5HT2A_HUMAN | 5-hydroxytryptamine receptor 2A | -9.28 | -9.46 | N/A | 46.55% | CHEMBL1084976 |
| Amantadine | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -6.13 | -5.40 | -5.97 | 23.68% | CHEMBL452719 |
| Alfentanil | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -8.27 | -7.80 | -8.56 | 38.29% | CHEMBL1729 |
| Pimecrolimus | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -6.33 | -3.18 | 4.07 | 35.95% | CHEMBL1909065 |
| Levacetylmethadol | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -7.57 | -7.59 | -7.73 | 56.38% | CHEMBL1277769 |
| Rofecoxib | 5HT2B_HUMAN | 5-hydroxytryptamine receptor 2B | -8.55 | -8.80 | -8.40 | 35.59% | CHEMBL521805 |
| Amantadine | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -5.68 | -6.03 | N/A | 40.00% | CHEMBL334255 |
| Alfentanil | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -7.98 | -8.46 | N/A | 38.29% | CHEMBL1729 |
| Pimecrolimus | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -6.51 | 3.42 | N/A | 35.95% | CHEMBL1909065 |
| Levacetylmethadol | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -7.52 | -7.73 | N/A | 58.89% | CHEMBL517712 |
| Rofecoxib | 5HT2C_HUMAN | 5-hydroxytryptamine receptor 2C | -8.99 | -9.56 | N/A | 46.55% | CHEMBL1084721 |
| Amantadine | AA1R_HUMAN | adenosine A1 receptor | -5.58 | -5.75 | -6.12 | 14.29% | CHEMBL3955407 |
| Alfentanil | AA1R_HUMAN | adenosine A1 receptor | -7.54 | -7.79 | -7.69 | 33.33% | CHEMBL4065629 |
| Pimecrolimus | AA1R_HUMAN | adenosine A1 receptor | 7.44 | -5.98 | 35.07 | 35.81% | CHEMBL2070507 |
| Levacetylmethadol | AA1R_HUMAN | adenosine A1 receptor | -7.44 | -7.69 | -5.69 | 32.47% | CHEMBL3350613 |
| Rofecoxib | AA1R_HUMAN | adenosine A1 receptor | -9.35 | -9.21 | -9.43 | 25.86% | CHEMBL16997 |
| Amantadine | AA2AR_HUMAN | adenosine A2a receptor | -5.84 | -6.34 | -6.05 | 13.95% | CHEMBL3314905 |
| Alfentanil | AA2AR_HUMAN | adenosine A2a receptor | -7.42 | -7.28 | -8.12 | 35.45% | CHEMBL554840 |
| Pimecrolimus | AA2AR_HUMAN | adenosine A2a receptor | 2.50 | -0.57 | 35.27 | 36.80% | CHEMBL1950653 |
| Levacetylmethadol | AA2AR_HUMAN | adenosine A2a receptor | -6.90 | -6.93 | -7.87 | 32.47% | CHEMBL3350613 |
| Rofecoxib | AA2AR_HUMAN | adenosine A2a receptor | -9.50 | -9.28 | -9.60 | 36.44% | CHEMBL2042091 |
| Amantadine | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -6.21 | -6.11 | -6.72 | 56.52% | CHEMBL345241 |
| Alfentanil | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -9.09 | -8.79 | -6.61 | 38.46% | CHEMBL141853 |
| Pimecrolimus | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | 14.37 | 14.41 | 9.26 | 41.28% | CHEMBL1080631 |
| Levacetylmethadol | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -8.94 | -7.78 | -9.44 | 42.99% | CHEMBL1773490 |
| Rofecoxib | ACES_HUMAN | acetylcholinesterase (Cartwright blood group) | -8.92 | -9.06 | -10.59 | 33.61% | CHEMBL52347 |
| Amantadine | ACE_HUMAN | angiotensin I converting enzyme | -5.78 | -5.97 | -5.44 | 21.43% | CHEMBL110870 |
| Alfentanil | ACE_HUMAN | angiotensin I converting enzyme | -7.98 | -8.77 | -7.54 | 43.88% | CHEMBL78731 |
| Pimecrolimus | ACE_HUMAN | angiotensin I converting enzyme | -9.82 | 4.87 | ? | ? | ? |
| Levacetylmethadol | ACE_HUMAN | angiotensin I converting enzyme | -7.42 | -7.32 | -6.58 | 49.11% | CHEMBL1168 |
| Rofecoxib | ACE_HUMAN | angiotensin I converting enzyme | -8.13 | -8.60 | -7.38 | 37.96% | CHEMBL80667 |
| Amantadine | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -5.39 | N/A | N/A | 5.59% | CHEMBL386114 |
| Alfentanil | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -6.31 | N/A | N/A | 28.44% | CHEMBL386114 |
| Pimecrolimus | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -8.27 | N/A | N/A | 26.67% | CHEMBL386114 |
| Levacetylmethadol | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -6.42 | N/A | N/A | 24.31% | CHEMBL386114 |
| Rofecoxib | ACHA9_HUMAN | cholinergic receptor nicotinic alpha 9 subunit | -6.92 | N/A | N/A | 20.20% | CHEMBL386114 |
| Amantadine | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -6.96 | -7.13 | -7.66 | N/A | N/A |
| Alfentanil | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -4.74 | -2.82 | -5.23 | N/A | N/A |
| Pimecrolimus | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | ? | ? | ? | N/A | N/A |
| Levacetylmethadol | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -2.02 | -2.46 | -4.34 | N/A | N/A |
| Rofecoxib | ACHB2_HUMAN | cholinergic receptor nicotinic beta 2 subunit | -6.03 | -8.79 | -7.49 | N/A | N/A |
| Amantadine | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -7.16 | -5.22 | N/A | 56.52% | CHEMBL75880 |
| Alfentanil | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -8.00 | 3.38 | N/A | 49.64% | CHEMBL1243233 |
| Pimecrolimus | ACM1_HUMAN | cholinergic receptor muscarinic 1 | 46.08 | 104.68 | N/A | 45.98% | CHEMBL363895 |
| Levacetylmethadol | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -8.23 | 4.71 | N/A | 73.42% | CHEMBL285440 |
| Rofecoxib | ACM1_HUMAN | cholinergic receptor muscarinic 1 | -10.39 | -4.07 | N/A | 58.52% | CHEMBL2312368 |
| Amantadine | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -6.99 | -6.13 | N/A | 56.52% | CHEMBL75880 |
| Alfentanil | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -6.95 | -7.64 | N/A | 44.16% | CHEMBL1223804 |
| Pimecrolimus | ACM4_HUMAN | cholinergic receptor muscarinic 4 | 52.15 | 17.08 | N/A | 42.11% | CHEMBL313738 |
| Levacetylmethadol | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -8.01 | -4.44 | N/A | 73.42% | CHEMBL285440 |
| Rofecoxib | ACM4_HUMAN | cholinergic receptor muscarinic 4 | -10.42 | -9.33 | N/A | 42.75% | CHEMBL1180285 |
| Amantadine | ADRB2_HUMAN | adrenoceptor beta 2 | -6.16 | -6.11 | -6.06 | 19.40% | CHEMBL1332942 |
| Alfentanil | ADRB2_HUMAN | adrenoceptor beta 2 | -7.60 | -8.62 | -8.44 | 40.40% | CHEMBL1459608 |
| Pimecrolimus | ADRB2_HUMAN | adrenoceptor beta 2 | -6.14 | 9.06 | 13.36 | 33.58% | CHEMBL3973386 |
| Levacetylmethadol | ADRB2_HUMAN | adrenoceptor beta 2 | -6.21 | -7.06 | -8.31 | 46.73% | CHEMBL1082607 |
| Rofecoxib | ADRB2_HUMAN | adrenoceptor beta 2 | -9.03 | -8.98 | -8.85 | 38.31% | CHEMBL446840 |
| Amantadine | AGTR2_HUMAN | angiotensin II receptor type 2 | -5.87 | -5.99 | -5.83 | 8.08% | CHEMBL376286 |
| Alfentanil | AGTR2_HUMAN | angiotensin II receptor type 2 | -7.79 | -8.13 | -7.90 | 34.50% | CHEMBL348157 |
| Pimecrolimus | AGTR2_HUMAN | angiotensin II receptor type 2 | -10.54 | -9.96 | -10.55 | 27.59% | CHEMBL3350599 |
| Levacetylmethadol | AGTR2_HUMAN | angiotensin II receptor type 2 | -8.08 | -7.85 | -7.97 | 32.35% | CHEMBL3350599 |
| Rofecoxib | AGTR2_HUMAN | angiotensin II receptor type 2 | -8.89 | -8.83 | -9.06 | 26.47% | CHEMBL217673 |
| Amantadine | ALDR_HUMAN | aldo-keto reductase family 1 member B | -6.35 | -6.40 | -6.22 | 9.09% | CHEMBL173813 |
| Alfentanil | ALDR_HUMAN | aldo-keto reductase family 1 member B | -8.03 | -7.79 | -7.50 | 34.50% | CHEMBL344057 |
| Pimecrolimus | ALDR_HUMAN | aldo-keto reductase family 1 member B | -9.08 | -8.38 | -8.15 | 32.96% | CHEMBL249448 |
| Levacetylmethadol | ALDR_HUMAN | aldo-keto reductase family 1 member B | -6.36 | -6.88 | -6.43 | 33.33% | CHEMBL319244 |
| Rofecoxib | ALDR_HUMAN | aldo-keto reductase family 1 member B | -8.47 | -8.73 | -8.55 | 53.47% | CHEMBL319244 |
| Amantadine | AMPN_HUMAN | alanyl aminopeptidase, membrane | -5.97 | -5.38 | -5.19 | 38.24% | CHEMBL27519 |
| Alfentanil | AMPN_HUMAN | alanyl aminopeptidase, membrane | -7.96 | -8.07 | -7.95 | 38.10% | CHEMBL328470 |
| Pimecrolimus | AMPN_HUMAN | alanyl aminopeptidase, membrane | -8.48 | -9.78 | -8.76 | 33.33% | CHEMBL28650 |
| Levacetylmethadol | AMPN_HUMAN | alanyl aminopeptidase, membrane | -7.60 | -7.20 | -7.93 | 39.00% | CHEMBL1821978 |
| Rofecoxib | AMPN_HUMAN | alanyl aminopeptidase, membrane | -7.94 | -8.98 | -8.15 | 25.58% | CHEMBL1782887 |
| Amantadine | AOFA_HUMAN | monoamine oxidase A | -6.77 | -7.06 | -6.96 | 25.53% | CHEMBL3605361 |
| Alfentanil | AOFA_HUMAN | monoamine oxidase A | -8.53 | -8.49 | -8.88 | 37.44% | CHEMBL394864 |
| Pimecrolimus | AOFA_HUMAN | monoamine oxidase A | -4.78 | 3.24 | 36.97 | 27.45% | CHEMBL1629810 |
| Levacetylmethadol | AOFA_HUMAN | monoamine oxidase A | -7.44 | -6.87 | -6.68 | 51.35% | CHEMBL3330339 |
| Rofecoxib | AOFA_HUMAN | monoamine oxidase A | -9.34 | -9.92 | -9.20 | 44.00% | CHEMBL332223 |
| Amantadine | AOFB_HUMAN | monoamine oxidase B | -6.87 | -6.95 | -7.31 | 25.53% | CHEMBL3605359 |
| Alfentanil | AOFB_HUMAN | monoamine oxidase B | -9.57 | -8.75 | -8.72 | 31.33% | CHEMBL3781329 |
| Pimecrolimus | AOFB_HUMAN | monoamine oxidase B | 25.18 | 33.38 | 39.89 | 28.44% | CHEMBL4062286 |
| Levacetylmethadol | AOFB_HUMAN | monoamine oxidase B | -8.38 | -7.22 | -8.10 | 51.35% | CHEMBL3330339 |
| Rofecoxib | AOFB_HUMAN | monoamine oxidase B | -9.89 | -10.26 | -10.74 | 44.72% | CHEMBL1254624 |
| Amantadine | BACE1_HUMAN | beta-secretase 1 | -5.04 | -5.07 | -5.50 | 26.00% | CHEMBL583178 |
| Alfentanil | BACE1_HUMAN | beta-secretase 1 | -6.77 | -6.97 | -7.51 | 46.43% | CHEMBL1645517 |
| Pimecrolimus | BACE1_HUMAN | beta-secretase 1 | -9.21 | -9.26 | -8.97 | 46.97% | CHEMBL508218 |
| Levacetylmethadol | BACE1_HUMAN | beta-secretase 1 | -6.11 | -6.48 | -6.99 | 45.92% | CHEMBL1092504 |
| Rofecoxib | BACE1_HUMAN | beta-secretase 1 | -6.82 | -7.88 | -8.53 | 37.93% | CHEMBL3677230 |
| Amantadine | CAH2_HUMAN | carbonic anhydrase 2 | -4.92 | -4.75 | -4.20 | 46.43% | CHEMBL355555 |
| Alfentanil | CAH2_HUMAN | carbonic anhydrase 2 | -7.34 | -6.93 | -6.84 | 37.67% | CHEMBL183450 |
| Pimecrolimus | CAH2_HUMAN | carbonic anhydrase 2 | -7.36 | -7.85 | -6.99 | 39.68% | CHEMBL170725 |
| Levacetylmethadol | CAH2_HUMAN | carbonic anhydrase 2 | -6.55 | -6.49 | -6.45 | 44.21% | CHEMBL419006 |
| Rofecoxib | CAH2_HUMAN | carbonic anhydrase 2 | -6.93 | -8.39 | -8.27 | 50.00% | CHEMBL419006 |
| Amantadine | CASP1_HUMAN | caspase 1 | -4.61 | -4.84 | -5.77 | 16.44% | CHEMBL466565 |
| Alfentanil | CASP1_HUMAN | caspase 1 | -5.81 | -6.47 | -5.96 | 42.21% | CHEMBL322631 |
| Pimecrolimus | CASP1_HUMAN | caspase 1 | -6.88 | -7.18 | -7.27 | 47.31% | CHEMBL198845 |
| Levacetylmethadol | CASP1_HUMAN | caspase 1 | -4.95 | -6.98 | -5.52 | 48.94% | CHEMBL466565 |
| Rofecoxib | CASP1_HUMAN | caspase 1 | -6.21 | -7.26 | -5.91 | 30.34% | CHEMBL1222686 |
| Amantadine | CDK5_HUMAN | cyclin dependent kinase 5 | -6.86 | -6.80 | -5.52 | 23.64% | CHEMBL1994526 |
| Alfentanil | CDK5_HUMAN | cyclin dependent kinase 5 | -6.72 | -6.46 | -6.64 | 30.00% | CHEMBL1988141 |
| Pimecrolimus | CDK5_HUMAN | cyclin dependent kinase 5 | -8.03 | -8.51 | -4.99 | 28.88% | CHEMBL1980995 |
| Levacetylmethadol | CDK5_HUMAN | cyclin dependent kinase 5 | -5.76 | -4.74 | -5.38 | 44.57% | CHEMBL1988201 |
| Rofecoxib | CDK5_HUMAN | cyclin dependent kinase 5 | -8.15 | -9.21 | -8.58 | 29.14% | CHEMBL1996176 |
| Amantadine | CHLE_HUMAN | butyrylcholinesterase | -6.08 | -5.88 | -6.08 | 68.42% | CHEMBL498645 |
| Alfentanil | CHLE_HUMAN | butyrylcholinesterase | -7.91 | -8.44 | -7.94 | 38.06% | CHEMBL4060562 |
| Pimecrolimus | CHLE_HUMAN | butyrylcholinesterase | -5.30 | -2.03 | -9.49 | 41.28% | CHEMBL4079599 |
| Levacetylmethadol | CHLE_HUMAN | butyrylcholinesterase | -8.29 | -8.13 | -8.68 | 43.75% | CHEMBL603913 |
| Rofecoxib | CHLE_HUMAN | butyrylcholinesterase | -10.03 | -9.25 | -8.93 | 37.50% | CHEMBL492233 |
| Amantadine | CNR1_HUMAN | cannabinoid receptor 1 | -5.83 | -6.25 | -6.59 | 26.67% | CHEMBL483143 |
| Alfentanil | CNR1_HUMAN | cannabinoid receptor 1 | -7.72 | -9.03 | -8.12 | 39.57% | CHEMBL199873 |
| Pimecrolimus | CNR1_HUMAN | cannabinoid receptor 1 | -6.73 | -5.75 | -6.81 | 45.45% | CHEMBL3597330 |
| Levacetylmethadol | CNR1_HUMAN | cannabinoid receptor 1 | -5.97 | -7.75 | -5.43 | 45.92% | CHEMBL3321781 |
| Rofecoxib | CNR1_HUMAN | cannabinoid receptor 1 | -9.01 | -9.40 | -10.20 | 33.80% | CHEMBL361957 |
| Amantadine | CNR2_HUMAN | cannabinoid receptor 2 | -6.49 | -6.81 | N/A | 28.89% | CHEMBL1422818 |
| Alfentanil | CNR2_HUMAN | cannabinoid receptor 2 | -8.04 | -8.77 | N/A | 39.61% | CHEMBL1762292 |
| Pimecrolimus | CNR2_HUMAN | cannabinoid receptor 2 | 13.48 | 10.87 | N/A | 45.16% | CHEMBL3597331 |
| Levacetylmethadol | CNR2_HUMAN | cannabinoid receptor 2 | -8.23 | -8.01 | N/A | 49.47% | CHEMBL1765274 |
| Rofecoxib | CNR2_HUMAN | cannabinoid receptor 2 | -9.73 | -9.51 | N/A | 33.11% | CHEMBL3410820 |
| Amantadine | COLI_HUMAN | proopiomelanocortin | -6.50 | -6.27 | -4.87 | N/A | N/A |
| Alfentanil | COLI_HUMAN | proopiomelanocortin | -7.52 | -7.68 | -6.83 | N/A | N/A |
| Pimecrolimus | COLI_HUMAN | proopiomelanocortin | -7.08 | -7.65 | -7.78 | N/A | N/A |
| Levacetylmethadol | COLI_HUMAN | proopiomelanocortin | -6.92 | -6.38 | -6.09 | N/A | N/A |
| Rofecoxib | COLI_HUMAN | proopiomelanocortin | -9.17 | -9.06 | -7.70 | N/A | N/A |
| Amantadine | COMT_HUMAN | catechol-O-methyltransferase | -3.93 | -5.43 | -3.96 | 9.43% | CHEMBL3425731 |
| Alfentanil | COMT_HUMAN | catechol-O-methyltransferase | -5.52 | -6.06 | -5.47 | 25.59% | CHEMBL3819488 |
| Pimecrolimus | COMT_HUMAN | catechol-O-methyltransferase | -6.32 | -8.01 | -3.67 | 26.62% | CHEMBL3819488 |
| Levacetylmethadol | COMT_HUMAN | catechol-O-methyltransferase | -5.51 | -5.52 | -5.74 | 28.57% | CHEMBL3425731 |
| Rofecoxib | COMT_HUMAN | catechol-O-methyltransferase | -7.03 | -6.27 | -7.22 | 21.66% | CHEMBL953 |
| Amantadine | CRP_HUMAN | C-reactive protein | -4.54 | -4.59 | N/A | N/A | N/A |
| Alfentanil | CRP_HUMAN | C-reactive protein | -5.35 | -5.48 | N/A | N/A | N/A |
| Pimecrolimus | CRP_HUMAN | C-reactive protein | -5.59 | -6.48 | N/A | N/A | N/A |
| Levacetylmethadol | CRP_HUMAN | C-reactive protein | -5.14 | -4.71 | N/A | N/A | N/A |
| Rofecoxib | CRP_HUMAN | C-reactive protein | -6.35 | -6.23 | N/A | N/A | N/A |
| Amantadine | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | -6.74 | N/A | N/A | 9.23% | CHEMBL191413 |
| Alfentanil | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | -4.35 | N/A | N/A | 29.73% | CHEMBL3701188 |
| Pimecrolimus | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | 97.35 | N/A | N/A | 25.94% | CHEMBL3701188 |
| Levacetylmethadol | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | -5.19 | N/A | N/A | 27.27% | CHEMBL191413 |
| Rofecoxib | CXCR1_HUMAN | C-X-C motif chemokine receptor 1 | -6.39 | N/A | N/A | 26.09% | CHEMBL191413 |
| Amantadine | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -5.86 | -4.26 | -5.16 | 21.57% | CHEMBL2170299 |
| Alfentanil | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -8.23 | -6.86 | -7.36 | 31.77% | CHEMBL3893083 |
| Pimecrolimus | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -9.63 | -8.56 | -10.26 | 48.03% | CHEMBL1221944 |
| Levacetylmethadol | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -7.59 | -6.00 | -6.87 | 34.62% | CHEMBL366033 |
| Rofecoxib | CXCR4_HUMAN | C-X-C motif chemokine receptor 4 | -8.63 | -6.90 | -7.70 | 27.13% | CHEMBL126657 |
| Amantadine | DRD2_HUMAN | dopamine receptor D2 | -6.40 | N/A | N/A | 23.64% | CHEMBL78916 |
| Alfentanil | DRD2_HUMAN | dopamine receptor D2 | -7.37 | N/A | N/A | 45.45% | CHEMBL1242923 |
| Pimecrolimus | DRD2_HUMAN | dopamine receptor D2 | -8.88 | N/A | N/A | 35.95% | CHEMBL1909065 |
| Levacetylmethadol | DRD2_HUMAN | dopamine receptor D2 | -6.87 | N/A | N/A | 52.53% | CHEMBL2308105 |
| Rofecoxib | DRD2_HUMAN | dopamine receptor D2 | -8.01 | N/A | N/A | 38.89% | CHEMBL2368629 |
| Amantadine | DRD3_HUMAN | dopamine receptor D3 | -6.04 | N/A | N/A | 26.53% | CHEMBL165381 |
| Alfentanil | DRD3_HUMAN | dopamine receptor D3 | -7.42 | N/A | N/A | 40.14% | CHEMBL3354072 |
| Pimecrolimus | DRD3_HUMAN | dopamine receptor D3 | 3.59 | N/A | N/A | 48.33% | CHEMBL1200633 |
| Levacetylmethadol | DRD3_HUMAN | dopamine receptor D3 | -6.15 | N/A | N/A | 56.41% | CHEMBL936 |
| Rofecoxib | DRD3_HUMAN | dopamine receptor D3 | -9.52 | N/A | N/A | 38.89% | CHEMBL2368629 |
| Amantadine | DRD4_HUMAN | dopamine receptor D4 | -6.28 | -6.20 | N/A | 20.69% | CHEMBL1242950 |
| Alfentanil | DRD4_HUMAN | dopamine receptor D4 | -8.52 | -8.60 | N/A | 40.14% | CHEMBL3354072 |
| Pimecrolimus | DRD4_HUMAN | dopamine receptor D4 | -2.96 | -4.81 | N/A | 33.88% | CHEMBL282927 |
| Levacetylmethadol | DRD4_HUMAN | dopamine receptor D4 | -6.98 | -6.70 | N/A | 52.53% | CHEMBL2308105 |
| Rofecoxib | DRD4_HUMAN | dopamine receptor D4 | -8.49 | -8.43 | N/A | 29.11% | CHEMBL69759 |
| Amantadine | EDN1_HUMAN | endothelin 1 | -5.96 | N/A | N/A | N/A | N/A |
| Alfentanil | EDN1_HUMAN | endothelin 1 | -7.78 | N/A | N/A | N/A | N/A |
| Pimecrolimus | EDN1_HUMAN | endothelin 1 | -9.70 | N/A | N/A | N/A | N/A |
| Levacetylmethadol | EDN1_HUMAN | endothelin 1 | -6.35 | N/A | N/A | N/A | N/A |
| Rofecoxib | EDN1_HUMAN | endothelin 1 | -7.64 | N/A | N/A | N/A | N/A |
| Amantadine | ESR1_HUMAN | estrogen receptor 1 | -5.90 | -5.61 | -5.58 | 21.21% | CHEMBL1200623 |
| Alfentanil | ESR1_HUMAN | estrogen receptor 1 | -7.83 | -7.59 | -7.77 | 36.59% | CHEMBL1475062 |
| Pimecrolimus | ESR1_HUMAN | estrogen receptor 1 | -5.54 | -7.03 | -6.40 | 37.02% | CHEMBL4075710 |
| Levacetylmethadol | ESR1_HUMAN | estrogen receptor 1 | -6.93 | -7.34 | -8.17 | 44.00% | CHEMBL1222035 |
| Rofecoxib | ESR1_HUMAN | estrogen receptor 1 | -8.76 | -9.26 | -9.38 | 43.80% | CHEMBL3581689 |
| Amantadine | FABP5_HUMAN | fatty acid binding protein 5 | -5.45 | -4.20 | -4.65 | 23.08% | CHEMBL82293 |
| Alfentanil | FABP5_HUMAN | fatty acid binding protein 5 | -8.03 | -5.73 | -5.76 | 29.00% | CHEMBL3959018 |
| Pimecrolimus | FABP5_HUMAN | fatty acid binding protein 5 | 8.86 | -7.25 | -7.23 | 22.76% | CHEMBL3943278 |
| Levacetylmethadol | FABP5_HUMAN | fatty acid binding protein 5 | -8.03 | -5.15 | -5.20 | 23.20% | CHEMBL212860 |
| Rofecoxib | FABP5_HUMAN | fatty acid binding protein 5 | -8.44 | -6.22 | -6.03 | 22.70% | CHEMBL212860 |
| Amantadine | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -6.25 | N/A | N/A | 40.00% | CHEMBL334255 |
| Alfentanil | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -7.15 | N/A | N/A | 34.56% | CHEMBL407135 |
| Pimecrolimus | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -8.14 | N/A | N/A | 35.15% | CHEMBL1221512 |
| Levacetylmethadol | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -6.56 | N/A | N/A | 46.46% | CHEMBL305660 |
| Rofecoxib | FYN_HUMAN | FYN proto-oncogene, Src family tyrosine kinase | -9.04 | N/A | N/A | 29.09% | CHEMBL1221512 |
| Amantadine | GLRA3_HUMAN | glycine receptor alpha 3 | -5.92 | -5.94 | -5.95 | 4.64% | CHEMBL4070615 |
| Amantadine | GLRA3_HUMAN | glycine receptor alpha 3 | -7.26 | N/A | N/A | 4.64% | CHEMBL4070615 |
| Alfentanil | GLRA3_HUMAN | glycine receptor alpha 3 | -7.82 | -7.83 | -7.56 | 24.08% | CHEMBL4070615 |
| Alfentanil | GLRA3_HUMAN | glycine receptor alpha 3 | -8.90 | N/A | N/A | 24.08% | CHEMBL4070615 |
| Pimecrolimus | GLRA3_HUMAN | glycine receptor alpha 3 | -7.67 | -6.64 | -7.26 | 19.93% | CHEMBL4070615 |
| Pimecrolimus | GLRA3_HUMAN | glycine receptor alpha 3 | -6.80 | N/A | N/A | 19.93% | CHEMBL4070615 |
| Levacetylmethadol | GLRA3_HUMAN | glycine receptor alpha 3 | -7.55 | -7.00 | -7.00 | 17.81% | CHEMBL4070615 |
| Levacetylmethadol | GLRA3_HUMAN | glycine receptor alpha 3 | -8.14 | N/A | N/A | 17.81% | CHEMBL4070615 |
| Rofecoxib | GLRA3_HUMAN | glycine receptor alpha 3 | -8.90 | -9.16 | -8.83 | 19.40% | CHEMBL4070615 |
| Rofecoxib | GLRA3_HUMAN | glycine receptor alpha 3 | -9.56 | N/A | N/A | 19.40% | CHEMBL4070615 |
| Amantadine | GRM5_HUMAN | glutamate metabotropic receptor 5 | -6.87 | -4.63 | -4.89 | 38.24% | CHEMBL1783985 |
| Alfentanil | GRM5_HUMAN | glutamate metabotropic receptor 5 | -6.93 | -6.31 | -6.10 | 40.12% | CHEMBL3939327 |
| Pimecrolimus | GRM5_HUMAN | glutamate metabotropic receptor 5 | 65.78 | 77.47 | 69.91 | 30.77% | CHEMBL3086720 |
| Levacetylmethadol | GRM5_HUMAN | glutamate metabotropic receptor 5 | -4.55 | -1.44 | -1.18 | 42.59% | CHEMBL92162 |
| Rofecoxib | GRM5_HUMAN | glutamate metabotropic receptor 5 | -8.77 | -8.64 | -7.93 | 32.06% | CHEMBL92162 |
| Amantadine | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -5.46 | -4.46 | -5.44 | 11.54% | CHEMBL3134492 |
| Alfentanil | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -6.76 | -6.72 | -6.86 | 41.52% | CHEMBL3425956 |
| Pimecrolimus | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -7.75 | -8.37 | -6.92 | 25.24% | CHEMBL3650224 |
| Levacetylmethadol | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -6.95 | -6.17 | -6.10 | 25.29% | CHEMBL3698265 |
| Rofecoxib | HPGDS_HUMAN | hematopoietic prostaglandin D synthase | -7.86 | -7.60 | -6.88 | 24.08% | CHEMBL572528 |
| Amantadine | HRH1_HUMAN | histamine receptor H1 | -5.20 | N/A | N/A | 22.41% | CHEMBL571174 |
| Alfentanil | HRH1_HUMAN | histamine receptor H1 | -6.43 | N/A | N/A | 45.45% | CHEMBL1242923 |
| Pimecrolimus | HRH1_HUMAN | histamine receptor H1 | 68.56 | N/A | N/A | 31.02% | CHEMBL1278112 |
| Levacetylmethadol | HRH1_HUMAN | histamine receptor H1 | -3.67 | N/A | N/A | 59.52% | CHEMBL914 |
| Rofecoxib | HRH1_HUMAN | histamine receptor H1 | -7.85 | N/A | N/A | 31.11% | CHEMBL908 |
| Amantadine | HYES_HUMAN | epoxide hydrolase 2 | -6.05 | -6.79 | -6.50 | 39.39% | CHEMBL69663 |
| Alfentanil | HYES_HUMAN | epoxide hydrolase 2 | -7.98 | -7.98 | -8.01 | 42.25% | CHEMBL549576 |
| Pimecrolimus | HYES_HUMAN | epoxide hydrolase 2 | -8.61 | -2.61 | -8.71 | 42.00% | CHEMBL561665 |
| Levacetylmethadol | HYES_HUMAN | epoxide hydrolase 2 | -7.71 | -6.79 | -7.38 | 53.27% | CHEMBL2070334 |
| Rofecoxib | HYES_HUMAN | epoxide hydrolase 2 | -9.99 | -8.65 | -8.33 | 45.00% | CHEMBL4071682 |
| Amantadine | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -4.92 | N/A | N/A | 15.38% | CHEMBL1762621 |
| Alfentanil | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -5.83 | N/A | N/A | 34.62% | CHEMBL2208034 |
| Pimecrolimus | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -7.08 | N/A | N/A | 48.98% | CHEMBL1672879 |
| Levacetylmethadol | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -4.93 | N/A | N/A | 33.02% | CHEMBL1253688 |
| Rofecoxib | IKKB_HUMAN | inhibitor of nuclear factor kappa B kinase subunit beta | -9.33 | N/A | N/A | 38.71% | CHEMBL3114503 |
| Amantadine | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -5.69 | -6.23 | N/A | 57.14% | CHEMBL448741 |
| Alfentanil | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -7.61 | -7.38 | N/A | 38.46% | CHEMBL1008 |
| Pimecrolimus | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -10.78 | -9.96 | N/A | 92.67% | CHEMBL269732 |
| Levacetylmethadol | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -7.14 | -6.63 | N/A | 59.52% | CHEMBL914 |
| Rofecoxib | MDR1_HUMAN | ATP binding cassette subfamily B member 1 | -8.53 | -9.01 | N/A | 41.73% | CHEMBL2336636 |
| Amantadine | MIF_HUMAN | macrophage migration inhibitory factor | -4.40 | -6.37 | -5.60 | 11.54% | CHEMBL233248 |
| Alfentanil | MIF_HUMAN | macrophage migration inhibitory factor | -6.67 | -6.89 | -5.50 | 23.50% | CHEMBL554271 |
| Pimecrolimus | MIF_HUMAN | macrophage migration inhibitory factor | 55.31 | -6.60 | -5.75 | 31.32% | CHEMBL2375651 |
| Levacetylmethadol | MIF_HUMAN | macrophage migration inhibitory factor | -5.59 | -6.23 | -5.95 | 31.39% | CHEMBL497598 |
| Rofecoxib | MIF_HUMAN | macrophage migration inhibitory factor | -7.24 | -8.50 | -6.69 | 23.89% | CHEMBL3409229 |
| Amantadine | MK01_HUMAN | mitogen-activated protein kinase 1 | -4.87 | -5.30 | -6.03 | 12.77% | CHEMBL547 |
| Alfentanil | MK01_HUMAN | mitogen-activated protein kinase 1 | -6.36 | -7.08 | -7.23 | 38.67% | CHEMBL3398602 |
| Pimecrolimus | MK01_HUMAN | mitogen-activated protein kinase 1 | -7.32 | -7.60 | -4.79 | 33.46% | CHEMBL555017 |
| Levacetylmethadol | MK01_HUMAN | mitogen-activated protein kinase 1 | -5.05 | -6.16 | -6.52 | 38.46% | CHEMBL3752989 |
| Rofecoxib | MK01_HUMAN | mitogen-activated protein kinase 1 | -8.60 | -8.14 | -7.20 | 53.47% | CHEMBL319244 |
| Amantadine | MK03_HUMAN | mitogen-activated protein kinase 3 | -5.67 | -5.41 | -5.59 | 12.50% | CHEMBL3113587 |
| Alfentanil | MK03_HUMAN | mitogen-activated protein kinase 3 | -6.87 | -6.72 | -7.54 | 30.65% | CHEMBL3590107 |
| Pimecrolimus | MK03_HUMAN | mitogen-activated protein kinase 3 | -6.48 | -8.41 | -8.32 | 33.46% | CHEMBL555017 |
| Levacetylmethadol | MK03_HUMAN | mitogen-activated protein kinase 3 | -5.40 | -5.71 | -5.74 | 31.45% | CHEMBL3113587 |
| Rofecoxib | MK03_HUMAN | mitogen-activated protein kinase 3 | -8.84 | -8.77 | -8.14 | 24.00% | CHEMBL555017 |
| Amantadine | MTOR_HUMAN | mechanistic target of rapamycin kinase | -6.55 | -6.40 | -6.35 | 18.57% | CHEMBL3972399 |
| Alfentanil | MTOR_HUMAN | mechanistic target of rapamycin kinase | -9.17 | -8.56 | -8.64 | 40.76% | CHEMBL411735 |
| Pimecrolimus | MTOR_HUMAN | mechanistic target of rapamycin kinase | -8.96 | -8.89 | -8.17 | 92.67% | CHEMBL269732 |
| Levacetylmethadol | MTOR_HUMAN | mechanistic target of rapamycin kinase | -9.00 | -9.08 | -8.13 | 40.82% | CHEMBL3972399 |
| Rofecoxib | MTOR_HUMAN | mechanistic target of rapamycin kinase | -9.40 | -9.45 | -9.19 | 27.16% | CHEMBL3701064 |
| Amantadine | NEP_HUMAN | membrane metalloendopeptidase | -5.52 | -6.01 | -6.46 | 28.89% | CHEMBL211529 |
| Alfentanil | NEP_HUMAN | membrane metalloendopeptidase | -6.57 | -6.88 | -7.58 | 37.97% | CHEMBL51389 |
| Pimecrolimus | NEP_HUMAN | membrane metalloendopeptidase | -8.94 | -8.55 | -8.13 | 40.40% | CHEMBL434492 |
| Levacetylmethadol | NEP_HUMAN | membrane metalloendopeptidase | -6.19 | -5.94 | -5.80 | 53.93% | CHEMBL213404 |
| Rofecoxib | NEP_HUMAN | membrane metalloendopeptidase | -7.82 | -7.62 | -7.21 | 31.20% | CHEMBL81232 |
| Amantadine | NK1R_HUMAN | tachykinin receptor 1 | -6.39 | -6.68 | -5.59 | 20.69% | CHEMBL143813 |
| Alfentanil | NK1R_HUMAN | tachykinin receptor 1 | -8.49 | -7.61 | -7.56 | 45.83% | CHEMBL2313628 |
| Pimecrolimus | NK1R_HUMAN | tachykinin receptor 1 | -8.78 | -9.64 | -9.74 | 41.49% | CHEMBL538131 |
| Levacetylmethadol | NK1R_HUMAN | tachykinin receptor 1 | -8.21 | -6.30 | -6.50 | 65.22% | CHEMBL209531 |
| Rofecoxib | NK1R_HUMAN | tachykinin receptor 1 | -8.91 | -9.40 | -9.00 | 30.81% | CHEMBL93184 |
| Amantadine | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -6.00 | -5.92 | -6.05 | 7.59% | CHEMBL284237 |
| Alfentanil | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -7.75 | -6.97 | -7.19 | 13.41% | CHEMBL284237 |
| Pimecrolimus | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -9.33 | -7.74 | -8.94 | 13.24% | CHEMBL2333945 |
| Levacetylmethadol | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -6.47 | -6.68 | -6.07 | 29.63% | CHEMBL284237 |
| Rofecoxib | NMDE1_HUMAN | glutamate ionotropic receptor NMDA type subunit 2A | -10.09 | -9.70 | -10.02 | 18.99% | CHEMBL2333945 |
| Amantadine | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -5.32 | -6.40 | -4.57 | 24.07% | CHEMBL3357791 |
| Alfentanil | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -8.33 | -9.32 | -6.34 | 30.25% | CHEMBL218017 |
| Pimecrolimus | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -0.95 | 15.23 | -6.50 | 21.71% | CHEMBL17350 |
| Levacetylmethadol | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -6.53 | -8.52 | -5.69 | 48.78% | CHEMBL3357791 |
| Rofecoxib | NMDE2_HUMAN | glutamate ionotropic receptor NMDA type subunit 2B | -9.75 | -9.01 | -9.61 | 24.80% | CHEMBL151174 |
| Amantadine | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -5.93 | -5.86 | -6.05 | 8.74% | CHEMBL419399 |
| Alfentanil | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -7.03 | -7.57 | -7.19 | 28.84% | CHEMBL399075 |
| Pimecrolimus | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -9.52 | -7.75 | -8.94 | 23.02% | CHEMBL399075 |
| Levacetylmethadol | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -6.53 | -6.70 | -6.07 | 31.50% | CHEMBL419399 |
| Rofecoxib | NMDZ1_HUMAN | glutamate ionotropic receptor NMDA type subunit 1 | -9.15 | -9.92 | -10.02 | 18.59% | CHEMBL401253 |
| Amantadine | NOS1_HUMAN | nitric oxide synthase 1 | -6.49 | -6.22 | -5.75 | 31.71% | CHEMBL185441 |
| Alfentanil | NOS1_HUMAN | nitric oxide synthase 1 | -7.02 | -7.10 | -7.45 | 35.71% | CHEMBL317521 |
| Pimecrolimus | NOS1_HUMAN | nitric oxide synthase 1 | -10.00 | -10.09 | -8.63 | 29.57% | CHEMBL1270460 |
| Levacetylmethadol | NOS1_HUMAN | nitric oxide synthase 1 | -6.44 | -6.39 | -7.47 | 39.66% | CHEMBL1270460 |
| Rofecoxib | NOS1_HUMAN | nitric oxide synthase 1 | -8.67 | -8.50 | -9.05 | 22.15% | CHEMBL315966 |
| Amantadine | NOS2_HUMAN | nitric oxide synthase 2 | -5.64 | -5.27 | -5.53 | 45.00% | CHEMBL1783072 |
| Alfentanil | NOS2_HUMAN | nitric oxide synthase 2 | -6.38 | -7.35 | -6.15 | 35.62% | CHEMBL112747 |
| Pimecrolimus | NOS2_HUMAN | nitric oxide synthase 2 | 83.13 | -6.40 | ? | ? | ? |
| Levacetylmethadol | NOS2_HUMAN | nitric oxide synthase 2 | -5.07 | -6.22 | -7.54 | 33.33% | CHEMBL1762476 |
| Rofecoxib | NOS2_HUMAN | nitric oxide synthase 2 | -8.03 | -8.57 | -8.84 | 29.58% | CHEMBL1762474 |
| Amantadine | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -5.62 | -5.87 | -5.71 | 13.48% | CHEMBL1982413 |
| Alfentanil | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -7.09 | -7.17 | -7.09 | 35.96% | CHEMBL3934925 |
| Pimecrolimus | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -7.83 | -7.52 | -7.01 | 33.33% | CHEMBL444109 |
| Levacetylmethadol | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -5.98 | -7.08 | -6.39 | 30.25% | CHEMBL3912980 |
| Rofecoxib | NTRK1_HUMAN | neurotrophic receptor tyrosine kinase 1 | -10.36 | -9.51 | -9.77 | 29.94% | CHEMBL1794059 |
| Amantadine | OPRD_HUMAN | opioid receptor delta 1 | -5.49 | -4.82 | -4.75 | 25.00% | CHEMBL2112342 |
| Alfentanil | OPRD_HUMAN | opioid receptor delta 1 | -7.48 | -6.86 | -7.26 | 60.84% | CHEMBL169366 |
| Pimecrolimus | OPRD_HUMAN | opioid receptor delta 1 | -9.64 | 8.51 | 7.28 | 51.21% | CHEMBL3597152 |
| Levacetylmethadol | OPRD_HUMAN | opioid receptor delta 1 | -6.64 | -7.04 | -6.63 | 56.82% | CHEMBL290855 |
| Rofecoxib | OPRD_HUMAN | opioid receptor delta 1 | -8.59 | -7.75 | -7.53 | 34.59% | CHEMBL129693 |
| Amantadine | OPRK_HUMAN | opioid receptor kappa 1 | -5.76 | -6.32 | -6.21 | 52.00% | CHEMBL2432039 |
| Alfentanil | OPRK_HUMAN | opioid receptor kappa 1 | -8.79 | -7.74 | -7.73 | 59.84% | CHEMBL609147 |
| Pimecrolimus | OPRK_HUMAN | opioid receptor kappa 1 | -8.32 | -9.99 | -7.10 | 51.21% | CHEMBL3597152 |
| Levacetylmethadol | OPRK_HUMAN | opioid receptor kappa 1 | -7.63 | -6.85 | -6.98 | 66.67% | CHEMBL2260849 |
| Rofecoxib | OPRK_HUMAN | opioid receptor kappa 1 | -8.76 | -9.01 | -7.85 | 37.69% | CHEMBL279298 |
| Amantadine | OPRM_MOUSE | Mu-type opioid receptor | -6.50 | -5.31 | N/A | 18.31% | CHEMBL592 |
| Alfentanil | OPRM_MOUSE | Mu-type opioid receptor | -7.85 | -7.95 | N/A | 54.68% | CHEMBL2311157 |
| Pimecrolimus | OPRM_MOUSE | Mu-type opioid receptor | -9.24 | -10.25 | N/A | 49.48% | CHEMBL405663 |
| Levacetylmethadol | OPRM_MOUSE | Mu-type opioid receptor | -7.34 | -6.96 | N/A | 45.71% | CHEMBL440765 |
| Rofecoxib | OPRM_MOUSE | Mu-type opioid receptor | -8.36 | -8.02 | N/A | 31.74% | CHEMBL186041 |
| Amantadine | OPRX_HUMAN | opioid related nociceptin receptor 1 | -5.98 | -5.58 | -5.57 | 27.08% | CHEMBL53256 |
| Alfentanil | OPRX_HUMAN | opioid related nociceptin receptor 1 | -6.99 | -6.94 | -7.15 | 54.68% | CHEMBL28198 |
| Pimecrolimus | OPRX_HUMAN | opioid related nociceptin receptor 1 | -10.21 | -9.49 | -10.68 | 34.90% | CHEMBL1783822 |
| Levacetylmethadol | OPRX_HUMAN | opioid related nociceptin receptor 1 | -6.86 | -5.96 | -7.06 | 58.76% | CHEMBL364625 |
| Rofecoxib | OPRX_HUMAN | opioid related nociceptin receptor 1 | -8.11 | -7.32 | -7.53 | 30.08% | CHEMBL364625 |
| Amantadine | P2RX3_HUMAN | purinergic receptor P2X 3 | -4.15 | -3.91 | -4.26 | 10.74% | CHEMBL3674941 |
| Alfentanil | P2RX3_HUMAN | purinergic receptor P2X 3 | -5.65 | -5.35 | -5.29 | 38.89% | CHEMBL3669852 |
| Pimecrolimus | P2RX3_HUMAN | purinergic receptor P2X 3 | -7.14 | -6.29 | -6.17 | 36.06% | CHEMBL3669852 |
| Levacetylmethadol | P2RX3_HUMAN | purinergic receptor P2X 3 | -4.86 | -4.71 | -4.43 | 29.14% | CHEMBL3669705 |
| Rofecoxib | P2RX3_HUMAN | purinergic receptor P2X 3 | -6.02 | -5.98 | -5.68 | 25.95% | CHEMBL3669744 |
| Amantadine | P2Y12_HUMAN | purinergic receptor P2Y12 | -4.75 | -4.46 | -5.27 | 14.00% | CHEMBL299895 |
| Alfentanil | P2Y12_HUMAN | purinergic receptor P2Y12 | -7.13 | -2.60 | -7.01 | 36.52% | CHEMBL90804 |
| Pimecrolimus | P2Y12_HUMAN | purinergic receptor P2Y12 | -8.05 | 41.45 | 27.58 | 35.42% | CHEMBL272975 |
| Levacetylmethadol | P2Y12_HUMAN | purinergic receptor P2Y12 | -6.16 | -3.43 | -4.28 | 36.43% | CHEMBL88799 |
| Rofecoxib | P2Y12_HUMAN | purinergic receptor P2Y12 | -7.93 | -7.13 | -8.34 | 35.82% | CHEMBL88730 |
| Amantadine | PAR1_HUMAN | coagulation factor II thrombin receptor | -6.09 | N/A | N/A | 20.75% | CHEMBL80672 |
| Alfentanil | PAR1_HUMAN | coagulation factor II thrombin receptor | -5.97 | N/A | N/A | 43.33% | CHEMBL3658403 |
| Pimecrolimus | PAR1_HUMAN | coagulation factor II thrombin receptor | -6.84 | N/A | N/A | 38.16% | CHEMBL3925032 |
| Levacetylmethadol | PAR1_HUMAN | coagulation factor II thrombin receptor | -8.49 | N/A | N/A | 40.20% | CHEMBL3658406 |
| Rofecoxib | PAR1_HUMAN | coagulation factor II thrombin receptor | -7.36 | N/A | N/A | 29.05% | CHEMBL197523 |
| Amantadine | PDE4B_HUMAN | phosphodiesterase 4B | -5.34 | -5.28 | -5.47 | 12.50% | CHEMBL346083 |
| Alfentanil | PDE4B_HUMAN | phosphodiesterase 4B | -7.59 | -8.23 | -8.17 | 33.53% | CHEMBL239299 |
| Pimecrolimus | PDE4B_HUMAN | phosphodiesterase 4B | -8.56 | -8.65 | -7.77 | 40.28% | CHEMBL2063002 |
| Levacetylmethadol | PDE4B_HUMAN | phosphodiesterase 4B | -7.15 | -6.68 | -7.20 | 41.67% | CHEMBL144499 |
| Rofecoxib | PDE4B_HUMAN | phosphodiesterase 4B | -9.04 | -10.15 | -10.10 | 59.52% | CHEMBL197386 |
| Amantadine | PDE5A_HUMAN | phosphodiesterase 5A | -5.06 | -6.15 | -5.57 | 12.75% | CHEMBL554946 |
| Alfentanil | PDE5A_HUMAN | phosphodiesterase 5A | -7.73 | -8.27 | -7.70 | 31.00% | CHEMBL551948 |
| Pimecrolimus | PDE5A_HUMAN | phosphodiesterase 5A | -8.05 | -8.61 | -8.48 | 30.52% | CHEMBL190364 |
| Levacetylmethadol | PDE5A_HUMAN | phosphodiesterase 5A | -6.99 | -6.94 | -6.99 | 29.93% | CHEMBL190423 |
| Rofecoxib | PDE5A_HUMAN | phosphodiesterase 5A | -9.44 | -9.93 | -9.86 | 22.67% | CHEMBL554051 |
| Amantadine | PERM_HUMAN | myeloperoxidase | -5.68 | -5.97 | -5.41 | 15.38% | CHEMBL1630743 |
| Alfentanil | PERM_HUMAN | myeloperoxidase | -7.35 | -7.35 | -7.05 | 31.06% | CHEMBL1409565 |
| Pimecrolimus | PERM_HUMAN | myeloperoxidase | -7.07 | -8.79 | -10.30 | 22.22% | CHEMBL490 |
| Levacetylmethadol | PERM_HUMAN | myeloperoxidase | -7.33 | -7.69 | -7.62 | 37.08% | CHEMBL3892909 |
| Rofecoxib | PERM_HUMAN | myeloperoxidase | -8.52 | -8.77 | -8.73 | 20.71% | CHEMBL2347182 |
| Amantadine | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -4.83 | -6.02 | -6.28 | 14.29% | CHEMBL503071 |
| Alfentanil | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -6.34 | -7.57 | -6.88 | 29.63% | CHEMBL9197 |
| Pimecrolimus | PGH1_SHEEP | Prostaglandin G/H synthase 1 | 46.79 | 39.86 | 39.11 | 50.91% | CHEMBL502799 |
| Levacetylmethadol | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -4.24 | -5.21 | -6.68 | 44.87% | CHEMBL1945285 |
| Rofecoxib | PGH1_SHEEP | Prostaglandin G/H synthase 1 | -8.30 | -8.83 | -8.72 | 74.23% | CHEMBL259402 |
| Amantadine | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -4.69 | -4.93 | -5.70 | 13.79% | CHEMBL43864 |
| Alfentanil | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -3.17 | -4.71 | -6.64 | 31.61% | CHEMBL3809156 |
| Pimecrolimus | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | 84.54 | 54.53 | -1.06 | 50.30% | CHEMBL206765 |
| Levacetylmethadol | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | 0.14 | -5.26 | -5.43 | 47.44% | CHEMBL441414 |
| Rofecoxib | PGH2_HUMAN | prostaglandin-endoperoxide synthase 2 | -6.38 | -7.55 | -7.52 | 100.00% | CHEMBL122 |
| Amantadine | PPAP_HUMAN | acid phosphatase 3 | -6.42 | N/A | N/A | 5.33% | CHEMBL501717 |
| Alfentanil | PPAP_HUMAN | acid phosphatase 3 | -6.85 | N/A | N/A | 13.45% | CHEMBL507996 |
| Pimecrolimus | PPAP_HUMAN | acid phosphatase 3 | -7.65 | N/A | N/A | 11.82% | CHEMBL507996 |
| Levacetylmethadol | PPAP_HUMAN | acid phosphatase 3 | -7.37 | N/A | N/A | 19.64% | CHEMBL501717 |
| Rofecoxib | PPAP_HUMAN | acid phosphatase 3 | -8.11 | N/A | N/A | 14.38% | CHEMBL507996 |
| Amantadine | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -4.64 | -4.93 | -4.88 | 22.03% | CHEMBL1836976 |
| Alfentanil | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -7.14 | -7.37 | -7.57 | 40.46% | CHEMBL177854 |
| Pimecrolimus | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -8.07 | -6.10 | -7.73 | 49.07% | CHEMBL1834952 |
| Levacetylmethadol | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -5.82 | -6.46 | -6.66 | 47.06% | CHEMBL396109 |
| Rofecoxib | PPARG_HUMAN | peroxisome proliferator activated receptor gamma | -7.87 | -9.34 | -8.76 | 43.09% | CHEMBL144112 |
| Amantadine | PRGR_HUMAN | progesterone receptor | -6.32 | -6.04 | -5.89 | 18.92% | CHEMBL1684464 |
| Alfentanil | PRGR_HUMAN | progesterone receptor | -7.26 | -6.73 | -8.96 | 38.65% | CHEMBL600466 |
| Pimecrolimus | PRGR_HUMAN | progesterone receptor | 57.13 | 57.06 | 28.66 | 41.10% | CHEMBL1370 |
| Levacetylmethadol | PRGR_HUMAN | progesterone receptor | -5.95 | -7.00 | -8.86 | 39.23% | CHEMBL197161 |
| Rofecoxib | PRGR_HUMAN | progesterone receptor | -8.31 | -7.77 | -8.68 | 37.79% | CHEMBL2419306 |
| Amantadine | PTGES_HUMAN | prostaglandin E synthase | -5.77 | N/A | N/A | 16.88% | CHEMBL3919693 |
| Alfentanil | PTGES_HUMAN | prostaglandin E synthase | -6.83 | N/A | N/A | 46.75% | CHEMBL3910746 |
| Pimecrolimus | PTGES_HUMAN | prostaglandin E synthase | -6.58 | N/A | N/A | 31.82% | CHEMBL2315862 |
| Levacetylmethadol | PTGES_HUMAN | prostaglandin E synthase | -5.96 | N/A | N/A | 35.51% | CHEMBL3919693 |
| Rofecoxib | PTGES_HUMAN | prostaglandin E synthase | -7.06 | N/A | N/A | 39.04% | CHEMBL2071516 |
| Amantadine | SC6A4_HUMAN | solute carrier family 6 member 4 | -6.14 | -6.09 | -6.42 | 40.00% | CHEMBL334255 |
| Alfentanil | SC6A4_HUMAN | solute carrier family 6 member 4 | -8.85 | -8.71 | -8.89 | 44.97% | CHEMBL91418 |
| Pimecrolimus | SC6A4_HUMAN | solute carrier family 6 member 4 | 4.85 | -2.22 | 15.51 | 37.36% | CHEMBL86590 |
| Levacetylmethadol | SC6A4_HUMAN | solute carrier family 6 member 4 | -8.19 | -7.98 | -8.02 | 63.33% | CHEMBL598644 |
| Rofecoxib | SC6A4_HUMAN | solute carrier family 6 member 4 | -9.90 | -9.92 | -10.16 | 39.85% | CHEMBL574543 |
| Amantadine | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -6.83 | N/A | N/A | 16.92% | CHEMBL2152692 |
| Alfentanil | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -6.44 | N/A | N/A | 36.45% | CHEMBL2296310 |
| Pimecrolimus | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -6.96 | N/A | N/A | 32.64% | CHEMBL507974 |
| Levacetylmethadol | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -6.01 | N/A | N/A | 43.64% | CHEMBL206431 |
| Rofecoxib | SCN9A_HUMAN | sodium voltage-gated channel alpha subunit 9 | -7.67 | N/A | N/A | 28.02% | CHEMBL3682712 |
| Amantadine | TLR4_HUMAN | toll like receptor 4 | -7.14 | -7.21 | -5.91 | 13.75% | CHEMBL1223752 |
| Alfentanil | TLR4_HUMAN | toll like receptor 4 | -7.04 | -7.27 | -7.39 | 35.21% | CHEMBL1223752 |
| Pimecrolimus | TLR4_HUMAN | toll like receptor 4 | -8.84 | -9.15 | -9.18 | 51.47% | CHEMBL2364541 |
| Levacetylmethadol | TLR4_HUMAN | toll like receptor 4 | -7.39 | -7.09 | -7.31 | 38.57% | CHEMBL382272 |
| Rofecoxib | TLR4_HUMAN | toll like receptor 4 | -8.30 | -7.21 | -8.77 | 33.78% | CHEMBL4071705 |
| Amantadine | TNFA_HUMAN | tumor necrosis factor | -5.83 | N/A | N/A | 12.15% | CHEMBL3944621 |
| Alfentanil | TNFA_HUMAN | tumor necrosis factor | -7.59 | N/A | N/A | 32.28% | CHEMBL3806296 |
| Pimecrolimus | TNFA_HUMAN | tumor necrosis factor | -8.65 | N/A | N/A | 37.56% | CHEMBL3983488 |
| Levacetylmethadol | TNFA_HUMAN | tumor necrosis factor | -7.12 | N/A | N/A | 35.33% | CHEMBL3983488 |
| Rofecoxib | TNFA_HUMAN | tumor necrosis factor | -8.24 | N/A | N/A | 25.00% | CHEMBL2337619 |
| Amantadine | TRBM_HUMAN | thrombomodulin | -4.91 | -4.66 | N/A | N/A | N/A |
| Alfentanil | TRBM_HUMAN | thrombomodulin | -7.35 | -6.98 | N/A | N/A | N/A |
| Pimecrolimus | TRBM_HUMAN | thrombomodulin | -7.97 | -7.40 | N/A | N/A | N/A |
| Levacetylmethadol | TRBM_HUMAN | thrombomodulin | -6.67 | -5.84 | N/A | N/A | N/A |
| Rofecoxib | TRBM_HUMAN | thrombomodulin | -7.67 | -7.40 | N/A | N/A | N/A |
| Amantadine | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -5.40 | -5.24 | N/A | N/A | N/A |
| Alfentanil | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -6.36 | -6.94 | N/A | N/A | N/A |
| Pimecrolimus | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -9.07 | -7.14 | N/A | N/A | N/A |
| Levacetylmethadol | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -6.38 | -6.25 | N/A | N/A | N/A |
| Rofecoxib | TRPM4_HUMAN | transient receptor potential cation channel subfamily M member 4 | -7.06 | -7.41 | N/A | N/A | N/A |
| Amantadine | TRPM8_FICAL | Uncharacterized protein | -6.19 | N/A | N/A | N/A | N/A |
| Alfentanil | TRPM8_FICAL | Uncharacterized protein | -8.73 | N/A | N/A | N/A | N/A |
| Pimecrolimus | TRPM8_FICAL | Uncharacterized protein | -6.47 | N/A | N/A | N/A | N/A |
| Levacetylmethadol | TRPM8_FICAL | Uncharacterized protein | -7.94 | N/A | N/A | N/A | N/A |
| Rofecoxib | TRPM8_FICAL | Uncharacterized protein | -9.19 | N/A | N/A | N/A | N/A |
| Amantadine | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -6.08 | N/A | N/A | 18.52% | CHEMBL15848 |
| Alfentanil | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -7.72 | N/A | N/A | 30.61% | CHEMBL1395445 |
| Pimecrolimus | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -8.83 | N/A | N/A | 43.22% | CHEMBL455555 |
| Levacetylmethadol | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -6.75 | N/A | N/A | 43.36% | CHEMBL101775 |
| Rofecoxib | TRPV1_RAT | Transient receptor potential cation channel subfamily V member 1 | -8.37 | N/A | N/A | 35.67% | CHEMBL319078 |
| Amantadine | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -6.04 | -6.27 | N/A | N/A | N/A |
| Alfentanil | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -6.88 | -7.86 | N/A | N/A | N/A |
| Pimecrolimus | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -7.39 | -8.97 | N/A | N/A | N/A |
| Levacetylmethadol | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -5.79 | -6.79 | N/A | N/A | N/A |
| Rofecoxib | TRPV2_RABIT | Transient receptor potential cation channel subfamily V member 2 | -8.78 | -6.60 | N/A | N/A | N/A |
| Amantadine | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -5.88 | -5.89 | N/A | 10.83% | CHEMBL3692292 |
| Alfentanil | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -6.96 | -6.64 | N/A | 26.06% | CHEMBL3692258 |
| Pimecrolimus | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -7.58 | -6.16 | N/A | 26.03% | CHEMBL3664218 |
| Levacetylmethadol | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -6.66 | -5.04 | N/A | 34.01% | CHEMBL3664218 |
| Rofecoxib | TRPV3_HUMAN | transient receptor potential cation channel subfamily V member 3 | -6.71 | -7.53 | N/A | 25.00% | CHEMBL3696375 |
| Amantadine | TRXR1_HUMAN | thioredoxin reductase 1 | -5.81 | -5.37 | -4.57 | N/A | N/A |
| Alfentanil | TRXR1_HUMAN | thioredoxin reductase 1 | -7.66 | -7.69 | -6.21 | N/A | N/A |
| Pimecrolimus | TRXR1_HUMAN | thioredoxin reductase 1 | -7.55 | -8.81 | -9.39 | N/A | N/A |
| Levacetylmethadol | TRXR1_HUMAN | thioredoxin reductase 1 | -7.10 | -6.40 | -5.82 | N/A | N/A |
| Rofecoxib | TRXR1_HUMAN | thioredoxin reductase 1 | -7.86 | -7.48 | -6.65 | N/A | N/A |
| Amantadine | TRY1_HUMAN | serine protease 1 | -4.56 | N/A | N/A | 25.49% | CHEMBL289395 |
| Alfentanil | TRY1_HUMAN | serine protease 1 | -6.36 | N/A | N/A | 37.11% | CHEMBL421370 |
| Pimecrolimus | TRY1_HUMAN | serine protease 1 | -6.43 | N/A | N/A | 39.05% | CHEMBL309670 |
| Levacetylmethadol | TRY1_HUMAN | serine protease 1 | -5.08 | N/A | N/A | 50.00% | CHEMBL102081 |
| Rofecoxib | TRY1_HUMAN | serine protease 1 | -6.97 | N/A | N/A | 31.52% | CHEMBL99629 |